In vitro antifungal activity of the fourth generation fluoroquinolones against Candida isolates from human ocular infections

Sengul C. Ozdek, Darlene Miller, Patrick M. Flynn, Harry W Flynn

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Purpose: To evaluate and compare the in vitro antifungal activity of moxifloxacin and gatifloxacin against Candida species isolated from ocular infections. Methods: Tube microdilutions test was used to determine antifungal activity of the agents for 21 Candida isolates and one quality control strain. Drugs evaluated included topical preparations of fluoroquinolones (FQs), moxifloxacin (Vigamox), and gatifloxacin (Zymar). Serial dilutions of moxifloxacin (0.5%, 0.25%, 0.125%) and gatifloxacin (0.3%, 0.15%, 0.075%) were prepared for the microtube dilutions test. Aliquots (0.01 ul) were plated onto Sabouraud agar and colonies were counted. Results: Both drugs undiluted inhibited greater than 95% of growth at 24 hrs. There was no significant difference between moxifloxacin and gatifloxacin at undiluted concentrations (p = 1.00); however, the mean number of colony forming units in gatifloxacin group was significantly less than that of moxifloxacin at diluted concentrations of the drugs (p < 0.05). Conclusions: Current commercial topical preparations of moxifloxacin and gatifloxacin demonstrated a definite in vitro antifungal activity against ocular Candida species; however, clinical efficacy of these agents remains unproven. The greater inhibition of growth of organisms with gatifloxacin compared to moxifloxacin is possibly because of the presence of BAK in Zymar.

Original languageEnglish
Pages (from-to)347-351
Number of pages5
JournalOcular Immunology and Inflammation
Volume14
Issue number6
DOIs
StatePublished - Sep 1 2006

Fingerprint

Eye Infections
Fluoroquinolones
Candida
Pharmaceutical Preparations
gatifloxacin
In Vitro Techniques
Antifungal Agents
Growth
moxifloxacin
Quality Control
Agar
Stem Cells

Keywords

  • Fluoroquinolones
  • In vitro antifungal activity

ASJC Scopus subject areas

  • Ophthalmology
  • Immunology and Allergy

Cite this

In vitro antifungal activity of the fourth generation fluoroquinolones against Candida isolates from human ocular infections. / Ozdek, Sengul C.; Miller, Darlene; Flynn, Patrick M.; Flynn, Harry W.

In: Ocular Immunology and Inflammation, Vol. 14, No. 6, 01.09.2006, p. 347-351.

Research output: Contribution to journalArticle

@article{b2f441ffa40244aa899cfc31c5f5f5a0,
title = "In vitro antifungal activity of the fourth generation fluoroquinolones against Candida isolates from human ocular infections",
abstract = "Purpose: To evaluate and compare the in vitro antifungal activity of moxifloxacin and gatifloxacin against Candida species isolated from ocular infections. Methods: Tube microdilutions test was used to determine antifungal activity of the agents for 21 Candida isolates and one quality control strain. Drugs evaluated included topical preparations of fluoroquinolones (FQs), moxifloxacin (Vigamox), and gatifloxacin (Zymar). Serial dilutions of moxifloxacin (0.5{\%}, 0.25{\%}, 0.125{\%}) and gatifloxacin (0.3{\%}, 0.15{\%}, 0.075{\%}) were prepared for the microtube dilutions test. Aliquots (0.01 ul) were plated onto Sabouraud agar and colonies were counted. Results: Both drugs undiluted inhibited greater than 95{\%} of growth at 24 hrs. There was no significant difference between moxifloxacin and gatifloxacin at undiluted concentrations (p = 1.00); however, the mean number of colony forming units in gatifloxacin group was significantly less than that of moxifloxacin at diluted concentrations of the drugs (p < 0.05). Conclusions: Current commercial topical preparations of moxifloxacin and gatifloxacin demonstrated a definite in vitro antifungal activity against ocular Candida species; however, clinical efficacy of these agents remains unproven. The greater inhibition of growth of organisms with gatifloxacin compared to moxifloxacin is possibly because of the presence of BAK in Zymar.",
keywords = "Fluoroquinolones, In vitro antifungal activity",
author = "Ozdek, {Sengul C.} and Darlene Miller and Flynn, {Patrick M.} and Flynn, {Harry W}",
year = "2006",
month = "9",
day = "1",
doi = "10.1080/09273940600976953",
language = "English",
volume = "14",
pages = "347--351",
journal = "Ocular Immunology and Inflammation",
issn = "0927-3948",
publisher = "Informa Healthcare",
number = "6",

}

TY - JOUR

T1 - In vitro antifungal activity of the fourth generation fluoroquinolones against Candida isolates from human ocular infections

AU - Ozdek, Sengul C.

AU - Miller, Darlene

AU - Flynn, Patrick M.

AU - Flynn, Harry W

PY - 2006/9/1

Y1 - 2006/9/1

N2 - Purpose: To evaluate and compare the in vitro antifungal activity of moxifloxacin and gatifloxacin against Candida species isolated from ocular infections. Methods: Tube microdilutions test was used to determine antifungal activity of the agents for 21 Candida isolates and one quality control strain. Drugs evaluated included topical preparations of fluoroquinolones (FQs), moxifloxacin (Vigamox), and gatifloxacin (Zymar). Serial dilutions of moxifloxacin (0.5%, 0.25%, 0.125%) and gatifloxacin (0.3%, 0.15%, 0.075%) were prepared for the microtube dilutions test. Aliquots (0.01 ul) were plated onto Sabouraud agar and colonies were counted. Results: Both drugs undiluted inhibited greater than 95% of growth at 24 hrs. There was no significant difference between moxifloxacin and gatifloxacin at undiluted concentrations (p = 1.00); however, the mean number of colony forming units in gatifloxacin group was significantly less than that of moxifloxacin at diluted concentrations of the drugs (p < 0.05). Conclusions: Current commercial topical preparations of moxifloxacin and gatifloxacin demonstrated a definite in vitro antifungal activity against ocular Candida species; however, clinical efficacy of these agents remains unproven. The greater inhibition of growth of organisms with gatifloxacin compared to moxifloxacin is possibly because of the presence of BAK in Zymar.

AB - Purpose: To evaluate and compare the in vitro antifungal activity of moxifloxacin and gatifloxacin against Candida species isolated from ocular infections. Methods: Tube microdilutions test was used to determine antifungal activity of the agents for 21 Candida isolates and one quality control strain. Drugs evaluated included topical preparations of fluoroquinolones (FQs), moxifloxacin (Vigamox), and gatifloxacin (Zymar). Serial dilutions of moxifloxacin (0.5%, 0.25%, 0.125%) and gatifloxacin (0.3%, 0.15%, 0.075%) were prepared for the microtube dilutions test. Aliquots (0.01 ul) were plated onto Sabouraud agar and colonies were counted. Results: Both drugs undiluted inhibited greater than 95% of growth at 24 hrs. There was no significant difference between moxifloxacin and gatifloxacin at undiluted concentrations (p = 1.00); however, the mean number of colony forming units in gatifloxacin group was significantly less than that of moxifloxacin at diluted concentrations of the drugs (p < 0.05). Conclusions: Current commercial topical preparations of moxifloxacin and gatifloxacin demonstrated a definite in vitro antifungal activity against ocular Candida species; however, clinical efficacy of these agents remains unproven. The greater inhibition of growth of organisms with gatifloxacin compared to moxifloxacin is possibly because of the presence of BAK in Zymar.

KW - Fluoroquinolones

KW - In vitro antifungal activity

UR - http://www.scopus.com/inward/record.url?scp=33845680984&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33845680984&partnerID=8YFLogxK

U2 - 10.1080/09273940600976953

DO - 10.1080/09273940600976953

M3 - Article

VL - 14

SP - 347

EP - 351

JO - Ocular Immunology and Inflammation

JF - Ocular Immunology and Inflammation

SN - 0927-3948

IS - 6

ER -